Development of Herbal Liposomal gels for Enhanced Anti-Psoriatic Therapy: Incoporting Isolated antipsoriatic compound from Methanol extract of Mirabilis jalapa

Abstract

Introduction: Psoriasis, a chronic immune-mediated skin disorder, affects patients' quality of life significantly due to its associated physical, psychological, and economic burden. Conventional treatments often pose challenges, including limited efficacy and adverse effects. The present study aimed to formulate Isolated antipsoriatic compound from methanol extract of roots of Mirabilis jalapa, DTDO into a liposomal gel (DTDO-L) and investigate the therapeutic potential of DTDO-L in UV-B-induced psoriasis model.

Materials and Methods: The study employed a UV-B-induced psoriasis model to mimic human pathology, determining erythema, thickness, and scaling scores. Key biomarkers of inflammation and oxidative stress, including IL-6, TNF-α, IL-1β, and antioxidant parameters (SOD, CAT, GPx, GSH, and MDA), were quantified. The DTDO-L gel was compared against a standard tretinoin gel and other formulations, including a non-liposomal DTDO gel and MEM extract-loaded gel.

Results and Discussion: DTDO-L demonstrated superior efficacy in reducing psoriatic markers compared to standard treatments. It significantly normalized keratinocyte proliferation and reduced inflammatory cytokines (TNF-α, IL-6, and IL-1β), similar with previous studies on liposomal drug delivery systems. Oxidative stress parameters improved significantly in the DTDO-L group, emphasizing its antioxidative potential. The liposomal formulation's nanoscale size enhanced skin penetration and drug retention, addressing key limitations of traditional treatments. Comparative analysis with standard and non-liposomal formulations underscored the superior anti-inflammatory and antioxidant effects of DTDO-L.

Conclusion: The findings confirm the potential of DTDO-L liposomes as an effective therapeutic intervention for psoriasis. By improving drug delivery, reducing systemic side effects, and targeting multiple inflammatory pathways, DTDO-L offers a promising alternative to conventional therapies. Further clinical studies are warranted to establish its long-term safety and efficacy.